National Academies Press: OpenBook
« Previous: 4 Innovative Suggestions and Potential Solutions
Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×

References

Ahonkhai, V. 2012. Regulatory issues affecting MDR-TB SLDs. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Atun, R. 2012. Challenges and barriers to efficient operation of existing supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Cepheid. 2012. Cepheid announces first phase of Xpert MTB/RIF buy-down for high burden developing countries. http://www.cepheid.com/company/news-events/pressreleases/?releaseID=698417 (accessed October 1, 2012).

Comstock, G. 2012. Learning from other models: PEPFA R’s supply chain management system (SCMS). Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Ditiu, L. 2012. GDF vision for sld supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Fraser, H. S., J. Blaya, S. S. Choi, C. Bonilla, and D. Jazayeri. 2006. Evaluating the impact and costs of deploying an electronic medical record system to support TB treatment in Peru. AMIA Annual Symposium Proceedings 264-268.

Hedman, L. 2012. Quality of 2nd line medicines for tuberculosis. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

IOM (Institute of Medicine). 2009. Addressing the threat of drug-resistant tuberculosis: A realistic assessment of the challenge: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2011a. The emerging threat of drug-resistant tuberculosis in Southern Africa: Global and local challenges and solutions: Workshop summary. Washington, DC: The National Academies Press.

Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×

IOM. 2011b. The new profile of drug-resistant tuberculosis in Russia: A global and local perspective: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2012. Facing the reality of drug-resistant tuberculosis in India: Challenges and potential solutions: Workshop summary. Washington, DC: The National Academies Press.

Keshavjee, S. 2012. Background on the Green Light Committee and the second line tuberculosis drug supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Keshavjee, S., and P. Farmer. 2012. Tuberculosis, drug resistance, and the history of modern medicine. New England Journal of Medicine 367(10):931-936.

Keshavjee, S., and K. Seung. 2008. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. http://www.iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/IOM_MDRTB_whitepaper_2009_01_14_FINAL_Edited.pdf (accessed September 15, 2011).

Kimerling, M. 2012. SLD Financing Issues: IOM workshop on the global supply chain for second-line drugs for MDR-TB. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Mostaghim, S. 2012. MDR-TB drugs: Challenges and barriers to efficient operation of existing supply chain. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

MSF (Médecins Sans Frontières) and IUATLD (International Union Against Tuberculosis and Lung Disease). 2011. DR-TB drugs under the microscope: Sources and prices for drugresistant tuberculosis medicines. http://www.msfaccess.org/our-work/addressing-medicalchallenges/article/888 (accessed October 1, 2012).

MSH (Management Sciences for Health). 2011. Quality assurance for pharmaceuticals. http://www.msh.org/resource-center/publications/upload/MDS3-Ch19-QualityAssuranceNov2011.pdf (accessed November 13, 2012).

Ripin, D. 2012. Lessons learned from catalyzing and sustaining access to pediatric HIV treatments. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Sims, T. 2012. Creating innovative solutions for MDR-TB: Ideas from the MDR-TB innovation summit. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Wallengren, K., F. Scano, P. Nunn, B. Margot, S. Buthelezi, B. Williams, A. Pym, E. Y. Samuel, F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay. 2011. Drug-resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerging Infectious Diseases 17(10):1913-1916.

Walsh, J. A., and K. S. Warren. 1979. Selective primary health care: An interim strategy for disease control in developing countries. New England Journal of Medicine 301(18):967-974. WHO (World Health Organization). 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf (accessed October 1, 2012).

WHO. 2010. Global Tuberculosis Control: WHO report 2010. http://www.who.int/tb/publications/global_report/2010/en/index.html (accessed September 18, 2011).

Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×

Yadav, P. 2012. Supply chain for MDR-TB: Challenges and ideas for improvement. Presentation at IOM workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31-August 1, Washington, DC.

Zhao, Y., S. Xu, L. Wang, D. P. Chin, S. Wang, G. Jiang, H. Xia, Y. Zhou, Q. Li, X. Ou, Y. Pang, Y. Song, B. Zhao, H. Zhang, G. He, J. Guo, and Y. Wang. 2012. National Survey of Drug-Resistant Tuberculosis in China. New England Journal of Medicine 366(23):2161-2170.

Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×

This page is blank

Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Page 111
Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Page 112
Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Page 113
Suggested Citation:"References." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Page 114
Next: Appendix A: Workshop Agenda »
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary Get This Book
×
Buy Paperback | $45.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)—a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)—face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them.

This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review:

-To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks.

-The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain.

-What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President's Emergency Plan for AIDS Relief [PEPFAR])

- The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration

-Identification of potential innovative solutions to the problem

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!